SLS
Price:
$1.2
Market Cap:
$84.46M
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck...[Read more]
Industry
Biotechnology
IPO Date
2008-03-12
Stock Exchange
NASDAQ
Ticker
SLS
According to SELLAS Life Sciences Group, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.79. This represents a change of -5.49% compared to the average of -1.89 of the last 4 quarters.
The mean historical PE Ratio of SELLAS Life Sciences Group, Inc. over the last ten years is -2.01. The current -1.79 PE Ratio has changed 8.83% with respect to the historical average. Over the past ten years (40 quarters), SLS's PE Ratio was at its highest in in the December 2017 quarter at 4.60. The PE Ratio was at its lowest in in the September 2018 quarter at -17.94.
Average
-2.01
Median
-0.97
Minimum
-4.92
Maximum
-0.57
Discovering the peaks and valleys of SELLAS Life Sciences Group, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 384.96%
Maximum Annual PE Ratio = -0.57
Minimum Annual Increase = -77.03%
Minimum Annual PE Ratio = -4.92
Year | PE Ratio | Change |
---|---|---|
2023 | -0.79 | -29.97% |
2022 | -1.13 | -72.78% |
2021 | -4.14 | 49.54% |
2020 | -2.77 | 384.96% |
2019 | -0.57 | -1.89% |
2018 | -0.58 | -24.36% |
2017 | -0.77 | -6.33% |
2016 | -0.82 | -77.03% |
2015 | -3.57 | -27.47% |
2014 | -4.92 | -15.59% |
The current PE Ratio of SELLAS Life Sciences Group, Inc. (SLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.02
5-year avg
-1.88
10-year avg
-2.01
SELLAS Life Sciences Group, Inc.’s PE Ratio is greater than NLS Pharmaceutics AG (-75.24), greater than Mereo BioPharma Group plc (-12.39), less than Aravive, Inc. (0.08), greater than Day One Biopharmaceuticals, Inc. (-15.52), less than Reviva Pharmaceuticals Holdings, Inc. (-1.17), less than Eyenovia, Inc. (-0.20), less than Cognition Therapeutics, Inc. (-0.48), less than TransCode Therapeutics, Inc. (-0.37), greater than Kodiak Sciences Inc. (-1.80), greater than Ocuphire Pharma, Inc. (-2.14), less than Reviva Pharmaceuticals Holdings, Inc. (-1.17), greater than Protalix BioTherapeutics, Inc. (-12.86), greater than EyePoint Pharmaceuticals, Inc. (-4.73), greater than Zura Bio Limited (-6.18), less than Enveric Biosciences, Inc. (-0.29), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Immix Biopharma, Inc. (-2.22), less than Elevation Oncology, Inc. (-0.88), less than Annovis Bio, Inc. (-0.01), greater than Cassava Sciences, Inc. (-10.39), greater than Axsome Therapeutics, Inc. (-15.02), greater than Seres Therapeutics, Inc. (-5.26),
Company | PE Ratio | Market cap |
---|---|---|
-75.24 | $9.05M | |
-12.39 | $579.02M | |
0.08 | $2.95M | |
-15.52 | $1.37B | |
-1.17 | $33.95M | |
-0.20 | $9.42M | |
-0.48 | $16.81M | |
-0.37 | $6.51M | |
-1.80 | $345.21M | |
-2.14 | $31.74M | |
-1.17 | $37.45M | |
-12.86 | $123.70M | |
-4.73 | $614.26M | |
-6.18 | $196.53M | |
-0.29 | $3.25M | |
-0.00 | $2.82K | |
-2.22 | $45.29M | |
-0.88 | $37.00M | |
-0.01 | $90.51M | |
-10.39 | $184.02M | |
-15.02 | $4.70B | |
-5.26 | $149.74M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SELLAS Life Sciences Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SELLAS Life Sciences Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is SELLAS Life Sciences Group, Inc.'s PE Ratio?
How is the PE Ratio calculated for SELLAS Life Sciences Group, Inc. (SLS)?
What is the highest PE Ratio for SELLAS Life Sciences Group, Inc. (SLS)?
What is the 3-year average PE Ratio for SELLAS Life Sciences Group, Inc. (SLS)?
What is the 5-year average PE Ratio for SELLAS Life Sciences Group, Inc. (SLS)?
How does the current PE Ratio for SELLAS Life Sciences Group, Inc. (SLS) compare to its historical average?